Alumis (NASDAQ:ALMS) Given Buy Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Alumis (NASDAQ:ALMS) in a research note issued to investors on Friday morning,Benzinga reports. They currently have a $26.00 price objective on the stock.

Several other brokerages have also recently weighed in on ALMS. Cantor Fitzgerald reiterated an “overweight” rating on shares of Alumis in a research note on Thursday, November 14th. Robert W. Baird initiated coverage on shares of Alumis in a research note on Thursday, October 31st. They set an “outperform” rating and a $25.00 price target on the stock. Finally, Baird R W raised shares of Alumis to a “strong-buy” rating in a research report on Thursday, October 31st. Six analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $26.83.

Alumis Price Performance

Alumis stock opened at $8.82 on Friday. Alumis has a one year low of $7.66 and a one year high of $13.53. The firm’s fifty day moving average price is $10.21.

Hedge Funds Weigh In On Alumis

Several large investors have recently made changes to their positions in ALMS. Barclays PLC bought a new position in Alumis in the 3rd quarter worth approximately $197,000. Geode Capital Management LLC purchased a new position in shares of Alumis in the third quarter worth $3,266,000. State Street Corp bought a new position in shares of Alumis during the third quarter worth $866,000. Stifel Financial Corp purchased a new position in Alumis during the third quarter valued at $931,000. Finally, Samsara BioCapital LLC bought a new stake in Alumis in the 3rd quarter valued at $34,886,000.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.